The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a pH regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject.

The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.

The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.

The object of the invention is topical compositions comprising pea proteins and polyphenols and the use thereof for the treatment of local or generalised disorders caused by increased permeation of the natural epithelial barriers. Said disorders may be of bacterial, viral, inflammatory, allergic and/or fungal origin, or endogenous or idiopathic.

The object of the invention is topical compositions comprising pea proteins and polyphenols and the use thereof for the treatment of local or generalised disorders caused by increased permeation of the natural epithelial barriers. Said disorders may be of bacterial, viral, inflammatory, allergic and/or fungal origin, or endogenous or idiopathic.

The present invention relates to a capsule comprising a faecal composition for oral administration wherein the faecal composition comprises a stool fraction and a diluent, wherein the stool fraction comprises one or more non-pathogenic microorganisms, and wherein the diluent comprises a cryoprotectant resulting in a final concentration of cryoprotectant in the faecal composition below 8% (v/v) cryoprotectant.

The present invention relates to a capsule comprising a faecal composition for oral administration wherein the faecal composition comprises a stool fraction and a diluent, wherein the stool fraction comprises one or more non-pathogenic microorganisms, and wherein the diluent comprises a cryoprotectant resulting in a final concentration of cryoprotectant in the faecal composition below 8% (v/v) cryoprotectant.

Disclosed are formulations comprising niclosamide. The formulations disclosed may be used as a unisex and hormone-free on-demand contraceptive.

The present invention relates generally to the field of protease-responsive drug delivery hydrogels, uses thereof, and related methods of their production. More particularly, the invention relates to hydrogels which release anti-inflammatory agents upon reaction with inflammation-related proteases.

The present invention relates to Human Immunodeficiency Virus (HIV) treatment. In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer useful as a long acting HIV treatment.